CANNASSURE THERAPEUTICS LTD

Autres langues Cannassure Therapeutics Ltd

Actions

CSURE-M

IL0001110134

Marché Fermé - TEL AVIV STOCK EXCHANGE Autres places de cotation 16:24:02 02/05/2024			Varia. 5j.	Varia. 1 janv.
1 411 ^ILa	+1,51%		+6,41%	+192,13%

27/03	Cannassure Therapeutics Ltd publie ses résultats pour l'exercice clos le 31 décembre 2023	CI
2023	Cannassure Therapeutics Ltd publie ses résultats pour le semestre clos le 30 juin 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cannassure Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Cannassure Therapeutics Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	31/08/23
Cannassure Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	26/03/23
Cannassure Was Granted A Patent for an Oral Delivery Method of Cannabis and Cannabinoids Compositions by the Israel Patents Authority	09/08/21
DanCann Pharma A/S : publishes Year-end report for 2020	26/02/21
Cannassure Therapeutics : DanCann Pharma's strategic partner, Cannassure Therapeutics Ltd., enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO® technology	18/01/21
Lipidor : and Cannassure enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO technology	18/01/21
DanCann Pharma A/S : enter exclusive agreement with Cannassure Therapeutics to be multinational distributor for Scandinavia (Denmark, Norway, Sweden, and Finland)	15/12/20
Lipidor : publishes interim report for Q3 2020	19/11/20
Lipidor : announces positive outcome of feasibility study for development of topical medical cannabis products based on the company's AKVANO® technology	30/09/20
Cannassure Therapeutics : Ltd and Lipidor AB Enter a Feasibility Study and Licence Option Agreement for Development and Sales of Topical Medical Cannabis Products Based on AKVANO Technology	11/12/19
Lipidor (Nasdaq First North: LIPI) and Cannassure (TASE:CSURE) enter a feasibility study and licence option agreement for development and sales of topical medical cannabis products	10/12/19

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Dès maintenant, trouvez facilement les meilleurs investissements de demain !

Optimiser mes Profits

fermer